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Abstract 
Controlled release of Brain Derived Neurotrophic Factor to promote neuron survival 
following chronic electrode implantation 
Aswin K. Sundarakrishnan 
Advisors: Karen Moxon, PhD, Margaret A. Wheatley, PhD  
 
Chronic electrode implantation in the brain leads to the formation of a glial 
scar surrounding the implantation site. The glial scar, when formed, severely inhibits the 
long term in-vivo functionality of neural electrodes. Studies in the past have tried 
coating the neural electrodes using polymers with or without bioactive agents. However 
none report any success in alleviating the glial scar or show improvement in electrode 
recording capability. Previous studies have suggested the use of neurotrophin delivery 
from electrode coatings to promote neuron survival and improve electrode 
biocompatibility. In the current work, the feasibility of delivering Brain Derived 
Neurotrophic Factor (BDNF) from alginate thin film coatings on silicon electrodes was 
evaluated. 
Electrode coatings were manufactured via spinner coating using 0.45 µm 
filtered 2% (w/v) or 4% (w/v) alginate solutions on silicon wafer substrates. To crosslink 
the alginate two different methods of crosslinking were evaluated, the fast CaCl2 
crosslinking and the slow CaCO3-GDL crosslinking method. However CaCl2 
crosslinking using an aerosolized spray produced consistent alginate coatings compared 
to the CaCO3-GDL crosslinking method and was subsequently used for all experiments. 
Thickness measurements using the profilometer showed that CaCl2 crosslinked alginate 
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coatings in the micron level can be produced by spin coating 0.45 µm filtered, 4% 
alginate solutions at 1000 rpm for 30-60 seconds. When multiple layers of alginate were 
applied on top of one another, coatings of thicknesses ranging from 5 µm to 80 µm were 
produced via spinner coating. To simulate BDNF release, all alginate films were loaded 
with either model proteins (lysozyme or chymotrypsinogen) or poloxamer (p-188), a 
polymer that has been shown to have membrane-sealing properties. In-vitro release 
studies from all loaded films were conducted in PBS (pH 7.4) at 37°C until all protein or 
poloxamer was released. 
Results from the release studies showed rapid release profiles for both model 
proteins and p-188. Complete release of proteins and p-188 took place within the first 
three hours. This is well short of the anticipated 3-4 day release period required for 
BDNF. In order to prolong release for BDNF, the effect of addition of a poly-L-ornithine 
(PLO) coating on the alginate layer was evaluated. PLO coatings at three different 
concentrations, 0.1(w/v) %, 0.5% and 1% were applied on the surface of alginate films. 
Subsequent release studies showed very similar release profiles between the PLO-coated 
and the uncoated films, and were probably due to the detachment of the film from the 
silicon surface early in the release.  
The results of this study clearly show the feasibility of manufacturing 
neurotrophin releasing alginate coatings for silicon electrodes. The versatile coating 
method can be used to deliver a number of different compounds including proteins like 
neurotrophins and polymers like p-188. However to achieve controlled release over 
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longer periods of 3-4 days, alternate coating methods will need to be investigated. 
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1 INTRODUCTION 
1.1 Neural Implants 
Every year patients in the millions lose neural function due to traumatic injury 
(i.e., brain injury or spinal cord injury), congenital conditions, degenerative diseases 
(e.g., retinis pigmentosa or age related macular degeneration) or other neural 
disorders (Winter O. J., 2007). While damage to the Peripheral Nervous System 
(PNS) is often repaired naturally, damage to the Central Nervous System (CNS) 
cannot be repaired leading to permanent disability of the individual. However 
studies have shown that neural pathways upstream of injury remain active (Winter 
O. J., 2007). Neural implants could therefore be used to tap into these pathways to 
regain functionality (Winter O. J., 2007).  
A good example of a neural implant that is in used today is the prosthetic 
cochlear implant that is used for the treatment of deafness (Bell et al., 1998). In a 
normal ear of an individual, the hair cells receive a wave of vibrations which they 
then convert into action potentials in the adjacent auditory neurons (Bell et al., 1998). 
These action potentials are then taken to the CNS to be perceived as sound. In deaf 
people, cochlear implants bypass the damaged hair cells stimulating the auditory 
neurons directly, therefore completing the neural circuit to the CNS (Bell et al., 1998). 
However neural implants do have some disadvantages. One of the major 
problems with neural implants is their failure to provide long term in-vivo 
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recordings. Two major reasons have been noted for the failure of such implants (i) 
the mechanical failure of the implant itself: failure of the cable from the electrode to 
the signal conditioning device or loss of polymeric insulation of the microelectrode 
due to the corrosive extracellular environment and (ii) the formation of the glial scar 
surrounding the region of implantation rendering the implant useless because of its 
inability to record action potentials from neurons (Moxon K. A., 2007). While the 
former has been resolved the latter continues to be a major drawback for the long 
term in-vivo functionality of neural implants.  
1.2 Overall Objective 
The overall goal of this project was to improve the long term in-vivo 
functionality of silicon electrodes. To achieve this end goal we focused on improving 
the biocompatibility of the silicon electrodes by providing controlled release of Brain 
Derived Neurotrophic Factor (BDNF) from alginate electrode coatings. Currently 
there are very few studies that have successfully shown neurotrophin delivery from 
neural electrodes. Studies which have successfully delivered neurotrophins in the 
past have failed to optimize delivery parameters including, but not limited to the 
method of delivery, the amount of protein to be delivered and length of delivery. 
The specific aims of this particular project are as follows… 
• To determine the ability of spinner coating to produce alginate electrode 
coatings. The aim is to establish the right combination of material parameters 
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and spinner coating parameters required for manufacturing alginate electrode 
coatings of the required thickness. 
• To evaluate the feasibility of loading and releasing model proteins, lysozyme and 
chymotrypsinogen from alginate coatings. The aim is to figure out the 
appropriate method of protein loading and the feasibility of loading 
physiologically relevant quantities of protein in the alginate coatings.  
• To test if the coating is versatile and is able to deliver other neuroprotective 
substances like poloxamer (p-188).  
• To test the ability of poly-L-ornithine (PLO) coatings on alginate to provide 
controlled release of the model proteins and poloxamer (p-188). 
2 DESIGN ASPECTS 
2.1 Design Criteria 
2.1.1 Electrode coating material 
• The aim of the current study is to show in-vitro BDNF release from alginate 
coated silicon wafer substitutes. It is expected that the in-vitro studies from 
this project will pave way for the development of electrode coatings eluting 
protein in-vivo. Therefore the coating material used for the project would 
have to be extremely biocompatible. Also, the chosen material would have to 
biodegrade naturally without any cytotoxicity when implanted in-vivo. 
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• The material chosen for manufacturing the coatings would have to be easily 
available.  
• Previous studies have shown that material-protein interactions may exist 
(Wells and Sheardown, 2007). Some interactions are harmless while some 
others have been shown to lead to changes in the protein conformation. For 
example Transforming Growth Factor – β1 (TGF-β1) encapsulated in alginate 
beads have been shown to become inactive due to alginate-protein 
interactions (Gombotz and Wee, 1998). In comparison alginate-protein 
interactions were found to enhance bioactivity of Vascular Endothelial 
Growth Factor (VEGF) following encapsulation (Peters, 1998). Hence the 
chosen coating material should not render the protein (BDNF) inactive. 
• Cost will be a factor if more than one material is identified with proven 
therapeutic use. In such a situation the least expensive material will be 
chosen for manufacturing coatings.  
2.1.2 Coating method 
• Reproducibility of the coatings produced using the method will be important 
for future commercialization and use. Any variability in coating thickness 
must be at a minimum, if any.  
• The method chosen for manufacturing electrode coatings should be cost 
effective for it to be used on a frequent basis.  
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Table 2.1: Comparison of different methods for manufacturing electrode coatings 
 
 
Coating 
method 
Thickness of 
films 
produced 
Advantages Disadvantages References 
Solvent 
casting 
microns - 
few 
millimeters 
(i) Films of uniform 
thickness can be 
produced 
(i) Mold according to 
the dimensions of the 
electrode (micron scale) 
may be required  
(Lu P., 2001; 
Siemann, 2005) 
Electros
pinning 
nanometers 
- 
millimeters 
(i) Consistent 
micron level films 
can be produced  
(i) High voltage 
application may cause 
denaturation of protein 
dissolved in polymer 
solution (ii) 
Electrospinning of 
alginate alone is not 
possible, need an 
additive 
(Schiffman and 
Schauer, 2008) 
Spinner 
coating 
nanometers 
- microns 
(i) Extremely 
simple to use (ii) 
Thin films of the 
required thickness 
can be produced 
using this method 
(i) If protein is mixed 
with polymer and 
spinner coated, 
wastage of protein may 
occur 
(Cathell and 
Schauer, 2007) 
Layer-
by-Layer 
(LbL) 
angstroms - 
nanometers 
(i) Extremely 
simple process   
(i) Films don’t break 
down in 1xPBS. Need 
harsh ionic 
environments to fall 
apart (ii) micron level 
coatings may not be 
possible  
(He W., 2005; 
Ren K., 2005; He 
W., 2006) 
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2.2 Design Constraints 
2.2.1 Electrode coating 
• The electrode coatings that are manufactured should be as thin as possible. 
They should not exceed the dimensions of the electrode itself. Therefore the 
coatings should not exceed 50µm in thickness. A thicker coating could 
potentially inflict more damage to the brain tissue.  
• The electrode coatings manufactured using the chosen method should allow 
for loading of physiologically relevant quantities of protein. To calculate the 
amount of BDNF that would need to be loaded into the electrode coatings a 
literature search (Table 2.2) was performed, identifying studies that delivered 
BDNF to promote neuron survival. Information from these studies like 
volume of injury (mm3
 
 
 
 
), amount of BDNF delivered (µg/hr) and length of 
delivery (days) were used to calculate the amount of BDNF that would need 
to be delivered to promote neuron survival following silicon electrode 
implantation (Appendix-A). 
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Table 2.2: Literature search showing the amount of BDNF that would need to be 
delivered to promote neuron survival following silicon electrode implantation 
Study details 
References 
 
(Giehl M. 
K., 1996b) 
(Gillespie N. 
L., 2003) 
(Tuszynski 
et al., 1996) 
(Hammond, 
1999) 
(Vavrek et 
al., 2006) 
Neuron Type 
corticospin
al neurons 
auditory 
neurons 
hypogloss
al nerve 
corticospinal 
neurons 
corticospin
al neurons 
Volume of 
Injury Induced 
(mm^3) 
52 N/A N/A 52 N/A 
When did 
delivery start? 
Immediate
ly after 
injury 
5 days after 
ototoxin 
exposure 
Immediate
ly after 
injury 
Immediately 
after injury 
Immediate
ly after 
injury 
Amount of 
BDNF delivered 
(µg/hr) 
0.5 0.016 0.05 0.5 0.5 
Time of 
delivery (days) 
7 28 14 14 14 
End Result 
promotes 
survival 
promotes 
survival 
promotes 
survival 
promotes 
long term 
survival 
promotes 
connection
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3 IMPROVING THE BIOCOMPATIBILITY OF NEURAL 
IMPLANTS 
3.1 Nerve Injury 
When neural implants are inserted into the cortex they tear through nerve tissue, 
severing capillaries, extracellular matrix, glial and neuronal processes causing 
extensive damage at the site of electrode insertion (Polikov et al., 2005). The resulting 
mechanical damage triggers a foreign body response by activating platelets, clotting 
factors and macrophages. Immediately following the foreign body response the 
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body triggers a number of repair mechanisms to allow for fast recovery. However 
depending on the site of injury the repair may or may not occur.   
3.1.1 Peripheral Nervous System (PNS) Injury 
In the PNS any damage to the neurons is often repaired. Figure 3.1 shows 
a neuron in the PNS undergoing injury. As shown by the figure the axon of the 
injured neuron degenerates immediately following injury. Any axonal or myelin 
debris formed in the process is cleared by phagocytotic cells such as 
macrophages and Schwann cells. Once the debris is cleared, regeneration of the 
axon starts at the proximal end and continues towards the distal end to the target 
tissue (e.g., muscle fibers) as seen in the Figure 3.1.  
 
Figure 3.1: Regeneration of the axon following axotomy in the Peripheral Nervous 
System (figure reproduced from Schmidt and Leach, 2003) 
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3.1.2 Central Nervous System (CNS) Injury 
Unlike the PNS, injury in the Central Nervous System (CNS) cannot be 
repaired. This is mainly due to the inability of the nerves to regenerate due to the 
presence of inhibitory glycoproteins present in the extra cellular environment of 
the CNS. Figure 3.2 shows a neuron in the CNS undergoing injury.  
When a nerve is severed in the CNS, macrophage infiltration occurs just 
like in the PNS. However their recruitment is much slower compared to the PNS 
due to the blood-brain barrier, resulting in the delayed removal of the myelin 
debris at the site of injury (Schmidt and Leach, 2003). In addition to the above, 
up-regulation of cell adhesion molecules at the site of injury in the CNS is not 
comparable to the up-regulation seen in the PNS, therefore limiting macrophage 
recruitment further (Schmidt and Leach, 2003). Last but not the least of the 
problems, astrocytes found surrounding the region of injury in the CNS become 
reactive and form glial scars that inhibit any sort of regeneration from 
happening.  
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Figure 3.2: Regeneration of the axon following axotomy in the Central Nervous System 
(figure reproduced from Schmidt and Leach, 2003) 
 
3.1.3 Glial Scar Formation 
A number of studies have investigated the formation and progression of 
the glial scar. One study by Biran et al., studied the glial scar following chronic 
microelectrode implantation. In this study microelectrode implanted animals 
were compared to control animals which received only a stab wound using the 
same type of microelectrodes. At 2 and 4 weeks post-implantation 
immunostaining was performed to look for the presence of the different cell 
types including macrophages, astrocytes and neurons (Table 3.1).  
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Table 3.1: Summary of antibodies used for histology and immunostaining of brain tissue 
surrounding electrode implantation site (table reproduced from Biran et al., 2005)  
 
Figure 3.3 shows the results obtained from the immunostaining 
performed at the electrode implantation site. Together, both Figure 3.3A and 
Figure 3.3B describe the spatial location of the different cell types surrounding 
the microelectrode. As seen in Figure 3.3, immediately surrounding the 
microelectrodes are the macrophages visualized by ED1+ and Mac1+ staining. 
The peak intensity of the ED1+ (microglia and macrophage) immunoreactivity 
was found to be within a 50µm radius (Figure 3.3) surrounding the 
microelectrode surface with no significant change between 2 and 4 weeks (Biran 
et al., 2005).  
Compared to the macrophages (ED1+) the reactive astrocytes (GFAP+) 
were found starting at the 50µm radius extending over a distance greater than 
500 µm surrounding the implantation site (Figure 3.3). The astrocytes formed a 
sheath-like encapsulating layer surrounding the macrophage rich zone, with 
neurons being largely excluded from these zones (Figure 3.3) (Biran et al., 2005). 
Also, similar to ED1, there was no significant change in the intensity of GFAP 
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staining surrounding the microelectrodes both at 2 and 4 weeks post-
implantation. 
 
Figure 3.3: Immunostaining showing the spatial location of macrophages, astrocytes and 
neurons 4 weeks post-implantation (figure reproduced from Biran et al., 2005) 
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Staining for neuronal nuclei (NeuN) revealed an alarming ~40% 
reduction in the number of neuronal bodies within a 100µm radius (Figure 3.3) 
surrounding the microelectrode at 4 weeks post implantation (Biran et al., 2005). 
Apart from the reduction in the neuronal bodies a decrease in the neuron 
filament (NF) density and reactivity was also noticed up to 230µm surrounding 
the microelectrode surface. This reduction in neuronal density immediately 
surrounding the electrode is expected to be due to the death of neurons caused 
by the persistent inflammatory response consisting of activated microglia (Biran 
et al., 2005).  
3.1.4 Neuronal Death 
The inability of the neural electrodes to provide long term in-vivo 
recordings from neuronal processes is mainly due to the death of neurons 
immediately surrounding the electrodes. Therefore promoting neuron survival 
following electrode implantation will be important in ensuring electrode 
recording capacity.  
Neuronal death following chronic electrode implantation occurs in a 
sequential manner due to a number of different events. The first series of 
neuronal deaths occurs during electrode insertion. When electrodes are inserted 
into the cortex they axotomize neuronal processes leading to death of neurons 
(Polikov et al., 2005). Although some neuronal damage occurs during electrode 
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insertion, most of the neuronal death is expected to be due to the inflammatory 
response produced by the recruitment of macrophages in the surrounding area. 
Biran et al., observed a strong inverse correlation between the NF (neurons) 
staining and ED1 (macrophage) staining, implying that (i) macrophage activation 
leads to neuronal loss or (ii) neuronal damage at the site of injury leads to high 
macrophage activation due to another mechanism  or (iii) neurons are displaced 
from the electrode site by the inflammatory reaction (Biran et al., 2005).  
According to Biran et al., the macrophage activation leading to a 
phenomenon called “frustrated phagocytosis” is one of the major reasons for 
neuronal loss surrounding the electrode. (Biran et al., 2005). The phenomenon is 
tagged as a positive feedback mechanism where the macrophages continuously 
produce cytokines due to their inability to clear the insoluble silicon electrode. 
The death of neurons is therefore due to the toxicity created by cytokines like 
TNF-α, IL-1β and prostaglandins (Biran et al., 2005).  
A study conducted by Fitch et al. further provides support to this theory. 
Both studies are in agreement that the death of neurons is due to cytokine 
toxicity; however Fitch et al. suggests that some degree of mechanical damage 
also occurs to neurons due to astrocyte migration. Astrocytes are the primary 
support cells for neurons in the CNS (Schmidt and Leach, 2003) and migrate 
away from the macrophage rich zones. Therefore mechanical damage to the 
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neurons occurs as they were stretched, moved, pulled and torn between the 
migrating astrocytes (Fitch et al., 1999).  
3.2 Biocompatible Neural Implants 
Effective recording of action potentials from single neurons is possible only 
when the distance between the electrode and nearby neuronal cell body is of the 
order of cell dimensions, between 50 and 100 µm (Polikov et al., 2005). However 
with the glial scar forming at the very first day post-implantation neuronal death 
and movement occurs. Therefore there is a need for more biocompatible neural 
implants with long term in-vivo recording capacity. 
A number of different approaches have been used in the past to solve this 
problem. One approach that has been studied is to improve electrode 
biocompatibility by coating it with biocompatible polymers. Poly (lactic-co-glycolic 
acid) (PLGA) coated electrodes have been manufactured in the hope of alleviating 
the glial scarring in the brain (DiPaolo C. B., 2003). PLGA, a highly biocompatible 
and FDA (Food and Drug Administration) approved polymer was used to coat 
ceramic silicon electrodes. To study the effect of the PLGA coatings on the glial scar 
formation, in-vivo studies were conducted in Long-Evans rats.  
For the in-vivo study, coated silicon electrodes were implanted into the cortex of 
rats. Uncoated controls implanted into the cortex of the same animals were used for 
comparison. Immunohistochemistry (IHC) was then performed to look for the 
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presence of microglia, astrocytes and neurons surrounding the electrode 
implantation site. 
The results from IHC showed no significant difference between the coated and 
uncoated electrodes (DiPaolo C. B., 2003). The number of glia surrounding coated 
electrodes and uncoated controls remained the same (DiPaolo C. B., 2003). Also, the 
healthy neurons continued to be isolated from the electrode due to the presence of 
the microglia and reactive astrocytes (DiPaolo C. B., 2003).  
He et al., tried to alleviate the glial scar using a very similar, but different 
approach. In addition to the coating they also tried to immobilize laminin (LN), a 
bioactive protein. In comparison to DiPaolo et al., this study used a different method 
to coat the electrodes. Nano-coatings of polyethyleneimine (PEI)-laminin were 
manufactured using the layer-by-layer (LbL) approach. Using silicon wafers as the 
substrate, the authors created multilayers of oppositely charged PEI and laminin. 
Thickness measurements of the manufactured films showed that even coatings of up 
to 11 nm could be manufactured using the LbL technique (He W., 2005). To check the 
biocompatibility of the films produced, the authors performed two in-vitro assays, a 
neuron cell adhesion assay and a neurite outgrowth assay. The results from both 
assays showed that PEI-LN coatings were highly biocompatible (He W., 2005). 
Having obtained positive results from the in-vitro studies, the authors carried 
out in-vivo studies in rats (He W., 2006). PEI-LN coated electrodes were implanted 
into the cortex of male Sprague-Dawley rats. As controls they implanted uncoated 
electrodes into the cortex of the same animals. Once again very little difference was 
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noticed between the LN-coated and uncoated probes 1 week after implantation. The 
LN coated probes did not reduce the accumulation of macrophages or reactive 
astrocytes in the first week (He W., 2006). Also no difference in neuronal proximity 
to the electrode recording site or neuronal density between bare and LN coated 
probes was observed (He W., 2006).  
Failure of both the above studies clearly showed that coatings with or without 
protein/drug immobilization were not going to provide long term in-vivo 
functionality for electrodes. The coatings neither attracted neurons nor prevented the 
glial scar from forming. Recent studies have therefore shifted focus towards coatings 
that allow diffusion of pharmacological agent(s) or neurotrophins. Moxon et al., has 
suggested that delivery of neurotrophins could help ameliorate the short term 
impact of the microelectrode insertion and bind neurons to the microelectrode 
(Moxon K. A., 2007). One of the primary advantages of the drug delivery approach 
could be its ability to reach neurons beyond the glial scar region (He W., 2006).  
3.3 Neurotrophin delivery 
Neurotrophins are a family of proteins that regulate neuronal survival, axonal 
growth, synaptic plasticity and neurotransmission (Lu P., 2001). The neurotrophin 
family includes nerve growth Factor (NGF), brain derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), neurotrophin-6, ciliary 
neurotrophic factor, basic fibroblast growth factor, glial derived neurotrophic factor, 
cholinergic development factor and other possible factors (Tuszynski et al., 1996). 
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Among these growth factors NGF, BDNF and NT-3 have been delivered to the brain 
to aid in neuronal survival and/or growth. BDNF has been shown to prevent injury-
related motor neuronal degeneration (Tuszynski et al., 1996), adult basal forebrain 
cholinergic neuronal degradation (Tuszynski et al., 1996), and corticospinal neuronal 
degeneration following axotomy (Giehl M. K., 1996a). Table 2.2 shows a summary of 
some of the studies that report survival effects following BDNF delivery.  
BDNF promotes neuron survival by binding to specific tyrosine kinase receptor –
B (TrkB) in the target neurons. The receptor once activated has been shown to trigger 
one of two survival pathways, the PI3K pathway or the Erk pathway (Figure 3.4). 
While the former is straightforward and promotes survival directly the latter is 
dependent on infusion of calcium from calcium channels. Irrespective of the path 
taken, the final target of both pathways has been shown to be pro-apoptotic genes 
like Forkhead and Bad which facilitate neuronal survival (Sossin and Barker, 2007).  
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Figure 3.4: Pathways by which BDNF elicits its survival effects on neurons (figure 
reproduced from Sossin and Barket, 2007)  
 
For this particular study we hypothesized that BDNF delivery could help 
promote long term in-vivo functionality of neural electrodes, by helping neuron 
survival in the short term. The only major drawback to BDNF delivery, which has 
been suggested in the past, is the half life of the protein in-vivo. The half-life of 
BDNF in the plasma was been found to be as low as 3 hours (Kishino et al., 2001). 
Therefore to overcome this problem controlled release of the protein from a polymer 
over a sustainable period of time has been suggested (Vögelin et al., 2006).  
Vögelin et al., successfully showed the controlled release of BDNF using 
alginate microbeads ranging from 300-700 µm in diameter. In-vitro studies 
conducted by the authors showed that the alginate degraded slowly in phosphate 
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buffered saline (PBS) releasing BDNF for 16 days with a maximum of 25µg/ml per 
day (Vögelin et al., 2006). The authors also showed that the alginate helped maintain 
the bioactivity of the protein over time. The in-vivo studies showed that the BDNF, 
that was released, continued to support peripheral nerve regeneration at 4 and 10 
weeks post administration (Vögelin et al., 2006). Therefore controlled release of 
BDNF from alginate matrices could promote neuron survival following electrode 
implantation in the CNS.  
3.4 Poloxamer (p-188) 
Another neuroprotective agent that has received lot of attention is poloxamer (p-
188). Poloxamer is a water soluble, amphiphilic, triblock copolymer that has been 
approved by the FDA to be used a skin cleanser (Serbest et al., 2005). As shown in 
Figure 3.5 the polymer has two hydrophilic polyethylene oxide residues (PEO) on 
either side and a polypropylene oxide (PPO) residue in the center.  
 
Figure 3.5: The chemical structure of poloxamer (p-188), a polymer with membrane 
sealing properties a=80, b=27 (figure reproduced from Mao et al., 2004) 
 
Poloxamer when added to mechanically injured cells, has been found to seal 
plasma membranes, promoting cell viability and hence subsequent recovery (Serbest 
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et al., 2006). Serbest et al., treated mechanically injured PC12 cells, a subline of rat 
pheochromocytoma cell line with p-188. Results from the in-vitro study showed that 
p-188 promoted neuronal cell viability in a dose dependent manner.  For the current 
study we hypothesize that neurotrophin delivery along with poloxamer could 
enhance neuron survival following electrode injury. 
3.5 Alginate for drug delivery 
 The use of alginates as drug delivery vehicles is well documented. A 
number of studies have successfully shown controlled release of proteins from 
alginate matrices. Growth factors including Nerve Growth Factor (NGF), Vascular 
Endothelial Growth Factor (VEGF) and Transforming Growth Factor – β (TGF-β) 
have been delivered in the past using alginate hydrogels (Gombotz and Wee, 1998).  
Alginate, extracted from brown seaweed is a water-soluble, biocompatible, 
biodegradable, and inert biopolymer (Tobias et al., 2001). The linear polysaccharide 
is composed of repeated units of (1-4)-α-L-guluronic acid (G unit) and (1-4)-β-D-
mannuronic acid (M unit) in varying proportions (Figure 3.6) (Tobias et al., 2001). 
Within the linear polysaccharide the M and G monomers are sequentially assembled 
in either repeating (MM or GG) or alternating blocks (MG). Figure 3.6 shows the 
structure of L-guluronic acid and D-mannuronic acid residues.  
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Figure 3.6: The chemical structure of L-guluronic acid and D-mannuronic acid residues 
of alginate (figure reproduced from Gombotz and Wee, 1998)  
When sodium alginate is mixed with water at lower concentrations (< 2% (w/v) 
alginate in distilled water) it remains relatively liquid, but at higher concentrations 
(>2% (w/v) alginate in distilled water) the solution becomes extremely viscous and 
forms a physical gel. The viscosity of alginate solutions however is largely 
dependent on the molecular weight of the alginate used (Gombotz and Wee, 1998).  
In comparison to alginate solutions, crosslinked alginate gels have been found to 
have superior mechanical properties including longer degradation times’ in-vivo. 
Crosslinking of alginate is possible by exposing alginate solutions to divalent cations 
like Ca2+. The Ca2+ ions replace the sodium ions from the guluronic acids resulting 
in the formation of an egg box structure (Figure 3.7). Subsequently dimerization of 
alginate chains occurs resulting in the formation of a gel like network.  
Crosslinking of alginate is reversible. When crosslinked alginate gels are placed 
in a saline environment (similar to in-vivo body conditions) the Ca2+ ions are 
removed leading to de-crosslinking and de-stabilization. Any protein encapsulated 
in the crosslinked gel is released during this time. However de-crosslinking and 
degradation is not the only method of protein release from alginate gels. Protein 
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release has also been shown to occur by diffusion, through the network pores of the 
crosslinked gels.  
 
 
 
Figure 3.7: Eggbox structure formed during crosslinking of alginate following addition 
of divalent cations like Ca2+ (figure reproduced from Gombotz and Wee, 1998)  
 
One of the great advantages of using alginates for drug delivery is the ability to 
modify protein release by altering their material properties. In the past, material 
properties of alginate like concentration, molecular weight, pH, temperature and 
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crosslinking method have been varied to optimize protein release. Apart from 
material properties, several studies have used polycation coatings on crosslinked 
alginate gels to alter network pore size and degradation rate. Tobias et al., used poly-
L-ornithine (PLO) coatings on alginate beads to alter network pore size. In this 
study, genetically modified fibroblasts producing BDNF were encapsulated in 
alginate beads coated with PLO. The PLO coatings in this study were 
semipermeable. While allowing exchange of nutrients and waste products in and out 
of the alginate beads the coatings also provided immunoisolation. Due to the smaller 
network pore size they were able to selectively block any host immune cells from 
entering the beads, therefore providing isolation from the host’s immune system.  
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4 MATERIALS AND METHODS 
4.1 Methods for production of alginate coatings 
4.1.1 Preparation of Sterile Alginate 
The alginate electrode coatings developed in this project are intended for 
in-vivo application. Therefore there is a need for the preparation of sterile 
alginate. This is essential at this preliminary stage, even though in vivo work is 
not involved, to take into account any changes to the polymer composition and 
structure that may result from this sterilization process.  Sterile alginate was 
prepared using two different methods (i) filtration and (ii) autoclaving.  
Alginate powder was purchased from FMC Biopolymer (Drammen, 
Norway) (LF200M, Batch# S15596). The alginate had a G-block to M-block ratio 
of 35-45:55-65. The viscosity of 1% alginate solution prepared at 20°C is 200-400 
mPa as per manufacturer’s description.  
For preparing sterile alginate by filtration, a 1% (w/v) alginate solution 
was prepared by mixing small proportions of the alginate powder with distilled 
water until a homogenous solution was obtained. The solution was then filtered 
using a 0.45 µm Nalgene sterile syringe filter. A 1% (w/v) alginate solution was 
chosen because it was much harder to filter higher concentrations of alginate 
using syringe filters. The filtered 1% alginate solution was then placed in 50 ml 
tubes and instantaneously frozen using liquid nitrogen. The frozen 50 ml tubes 
were then placed in a -80° C freezer for 3-4 hours. After ensuring complete 
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freezing of the alginate, the solution was placed in a freeze drying apparatus for 
1-3 days. The freeze dried alginate was weighed using a scale to ensure complete 
loss of moisture. A 4% (w/v) alginate solution was then prepared using the freeze 
dried alginate by mixing with distilled water.  
To prepare autoclaved alginate, a 4% (w/v) alginate solution was 
prepared directly by mixing the alginate powder with distilled water. The 4% 
alginate solution was then autoclaved at 121°C for 35-45 minutes to obtain sterile 
alginate. The autoclaved 4% alginate solution and the filtered 4% alginate 
solution were visually inspected for changes in viscosity and their ability to form 
crosslinked gels.  
4.1.2 Protein Solubility Test 
The protein solubility test was performed to determine the effect of 
dissolving high pI proteins like BDNF in filtered 4% alginate solution. Due to the 
high cost of BDNF all experiments were carried out using model proteins with 
similar properties (molecular weight and pI) (Table 4.1). 
Lysozyme, α-chymotrypsin, and Bovine Serum Albumin (BSA) were 
obtained from Sigma-Aldrich (Saint Louis, MO). Chymotrypsinogen-A was 
purchased from Worthington Biochemical Corp. (Lakewood, NJ). A 8mg/ml 
solution of all proteins was prepared by dissolving the lyophilized powders of 
the different proteins in distilled water. The solubility of the different proteins in 
4% alginate was then tested by mixing 500µl-1ml of the 8mg/ml protein solution 
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in alginate. Observations were made on the ability of the proteins to completely 
go into solution.  
 
Table 4.1: Properties of different proteins used to test solubility in alginate 
Protein Isoelectric point Molecular weight (Da) 
Brain Derived Neurotrophic factor (BDNF) 9.01 27,200 
Bovine Serum Albumin (BSA) 4.7 66,000 
Chymotrypsin 9.1 25,000 
Lysozyme 11.35 14,700 
Chymotrypsinogen 9.1 25,000 
 
 
4.1.3 Cleaning Silicon wafers 
Silicon wafers ~500 µms thick were purchased from Silicon, Inc. (Kuna, 
Idaho). The purchased silicon wafers were cut using a diamond cutter or broken 
using a spatula to form 2cm x 2cm squares. The broken wafers were then cleaned 
to remove any organic impurities using the two step RCA (Radio corporation of 
America) cleaning process described below (Kern, 1990). All solutions for the 
cleaning process were purchased from Sigma-Aldrich (Saint Louis, MO). 
For the first cleaning step the wafers were placed on a holder and 
immersed into a beaker containing 250 ml of distilled water. To the distilled 
water 50 ml of 28% ammonium hydroxide solution (NH4OH) and 50 ml of 30% 
hydrogen peroxide (H2O2) were added in such a way that the ratio of water, 
NH4OH and H2O2 was 5:1:1. The beaker containing wafers and solution was 
then placed on a hot plate and allowed to boil for 5-10 minutes. The temperature 
 
28 
 
of the solution was under constant check and was not allowed to exceed 72°C. 
This was important to prevent the exothermic reaction from going out of control. 
When finished, the wafer was transferred to a container with overflowing 
distilled water. After 4-6 changes of water, the wafers were removed under 
flowing water to avoid any organic residue from re-depositing on the wafer 
surface. 
For the second cleaning step the same procedure as the one mentioned 
above was used. However to the 250 ml of distilled water, 50 ml of concentrated 
hydrochloric acid (conc. HCL) and 50 ml of 30% hydrogen peroxide (H2O2
4.1.4 Spinner coating parameters testing 
) were 
added in a volume ratio of 5:1:1. The solution with wafers was then allowed to 
boil for 5-10 mins before washing it again with 4-6 changes of water.  
After the two step cleaning process the wafers were allowed to dry 
overnight and wiped clean the next day. All washed wafers were stored in a 
closed dry chamber until ready to be used for experiments.   
To test the effect of alginate concentration, filtered 2% and 4% alginate 
solutions were prepared as mentioned above. Using a 1 ml syringe the 2% or 4% 
alginate solutions were applied on the surface of clean silicon wafers. Thin films 
of alginate were then produced by spin coating the silicon wafers in a WS-400B-
GNPP/LITE/AS spin processor (Laurell Technologies, North Wales, PA). To 
compare the effect of processing parameters, alginate was spin coated at different 
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operating velocities of 1000, 2000 and 3000 rpm for different durations of 30 and 
60 seconds.  
Following spinner coating, the alginate coatings were crosslinked by 
spraying a 10% solution of CaCl2 
4.1.5 Crosslinking of alginate coatings 
on the surface of the wafers. 
Two different systems of crosslinking were tested for producing alginate 
coatings (i) fast CaCl2 crosslinking or (ii) slow CaCO3+GDL (D-glucono- 
lactone) crosslinking. For fast crosslinking a 10% CaCl2 was sprayed on the 
surface of the alginate (figure - 4.1). A total of about ~300µl (3-4 sprays from a 3 
ounce spray bottle) of 10% CaCl2
 For the slow CaCO
 was sprayed using a spray bottle on the surface 
of the alginate coatings.  
3+GDL crosslinking, 1ml of filtered 4% alginate 
solution was mixed with 100 µl of 150 mM CaCO3 suspension and 100 µl of 150 
mM GDL (6-7 hour old). Experiments performed in the lab showed that fresh 
GDL took a very long time to crosslink the alginate gels. However when GDL 
was allowed to hydrolyze for 6-7 hours, crosslinking of alginate occurred within 
a period of 1-1.5 hours following mixing.  The solution of alginate, GDL and 
CaCO3
Figure 4.1
 was then spin coated on silicon wafers using the same method described 
above ( ). 
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Following crosslinking, all wafers with alginate were placed on a hot 
plate at the lowest temperature setting (30-40°C) until the coatings were 
moderately dry. Care was taken not to completely dry (visualized by the 
formation of air pockets or cracks on the alginate surface) the coatings, since it 
resulted in the formation of cracks. Thickness measurements of the alginate 
coatings were obtained using a profilometer (Zygo Corp., Middlefield, CT). 
 
 
Figure 4.1: Step-by-Step procedure for producing crosslinked alginate thin films using 
spinner coating 
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4.1.6 Production of multilayered alginate coatings 
To determine the feasibility of manufacturing thicker alginate coatings, 
spinner coating of multiple layers of alginate was performed. Four different 
wafers (three replicates for each type) with one, two, three or four coatings of 
alginate were spin coated using the spin coater (Figure 4.2).  
A solution of filtered 4% alginate was used for all experiments. The 
alginate solution was spin coated on silicon wafers at 1000 rpm for 30 seconds to 
obtain an even coating. The coating was then dried by placing the silicon wafer 
on a hot plate using the lowest temperature setting. Once dry, the wafer was 
again spin coated using 4% alginate at 1000 rpm for 30 seconds to obtain a 
second coating. The third and fourth coatings were applied using the same 
method.  
All wafers were finally crosslinked using a 10% solution of CaCl2
4.2 METHODS RELATED TO TESTING 
 (3-4 
sprays from a 3 ounce spray bottle) and subsequently placed inside a humidified 
chamber (100% humidity) overnight. Thickness measurements of the alginate 
coatings were then obtained using a profilometer (Zygo Corp., Middlefield, CT).  
4.2.1 Measuring thickness of alginate coatings using Profilometer  
To measure the thickness of the alginate coatings an optical white light 
profilometer was used (Zygo Corp., Middlefield, CT). Following crosslinking an 
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artificial step was scratched in each film using a razor blade and the height 
difference between the film surface and the underlying silicon substrate was 
measured at 4 nearby points in the region of the scratch.  
  
 
Figure 4.2: Step-by-Step procedure for producing multilayered alginate films coated 
with Poly-L-ornithine (PLO) 
 
4.2.2 Protein loading into alginate coatings: 
Traditionally protein loading into alginate beads has been performed 
either by (i) mixing the protein with the alginate solution prior to crosslinking or 
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(ii) by diffusing the protein into alginate coatings or beads after crosslinking. The 
former method of protein loading was not used due to strong alginate-protein 
interactions (Wells and Sheardown, 2007). 
Therefore all proteins were diffused into the alginate coatings once they 
were crosslinked with 10% CaCl2
4.2.3 Poloxamer (p-188) loading into alginate coatings 
. Once again two different methods were 
identified for protein loading by diffusion. To test both methods, two groups of 
three layered films manufactured using 4% filtered alginate solution was used 
(figure 4.2).  
The first group of dry alginate coatings was immersed into a beaker 
containing 10 ml of 4 mg/ml protein solution. The second group of dry alginate 
coatings was allowed to re-hydrate with 150-175 µl of either lysozyme or 
chymotrypsinogen to obtain a final loading of 750 µg of protein in each film 
(figure 4.2).  
To check the ability of the coatings to deliver poloxamer (p-188) was 
loaded into the alginate coatings. To track the release of the poloxamer from the 
alginate coatings, the poloxamer was fluorescently labeled with fluorescein 
isothiocyanate (FITC) to prepare FITC-p-188. The FITC-p-188 was loaded into the 
alginate coatings by rehydration, similar to protein loading. Dried alginate 
coatings prepared by spin coating were rehydrated using 150-175 µl of FITC-
p188 to obtain a final loading of 750 µg of poloxamer. 
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4.2.4 PLO coating of alginate 
To prolong protein release from alginate coatings the use of poly-L-
ornithine (PLO) coatings was evaluated. All PLO coated wafers containing 
protein/p-188 were used for release studies almost immediately. Poly-L-ornithine 
hydrochloride, molecular weight 15,000 – 30,000 Da was purchased from Sigma 
Aldrich (St. Louis, MO).  
Three different concentrations of PLO 0.1% (w/v), 0.5% or 1% were 
prepared in HEPES buffer (pH 7.4). Once prepared the different PLO solutions 
were sprayed on the surface of crosslinked alginate films (3-4 sprays from a 3 
ounce spray bottle). The wafers were then allowed to dry for 20-40 minutes at 
room temperature. During this time care was taken to prevent complete drying 
of all wafers. Complete drying of alginate coatings often produced cracks on the 
surface, making them unusable for subsequent release studies.  
Irrespective of the concentration of the PLO used all wafers were coated 
with a final layer of alginate. This was achieved by spraying the already PLO 
coated wafers with a 0.45 µm filtered 0.25% (w/v) alginate solution. The wafers 
were then allowed to dry again for 20-40 minutes. Figure 4.3 shows the schematic 
of the different coatings on the silicon wafers.   
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Figure 4.3: Schematic of spin coated wafers with alginate-PLO-alginate coatings 
 
 
4.2.5 Release studies 
For the release study all treatment wafers were re-hydrated with 150-175 
µl of either lysozyme or chymotrypsinogen or poloxamer (p-188) to obtain a final 
loading of 750 µg of protein/p-188 in each wafer (Figure 4.2). All control wafers 
were re-hydrated with an equal volume of distilled water. Table 4.2 shows the 
different control and treatment wafers used for the release studies.  
Release studies were conducted at 37 °C in beakers containing 5 ml of 1x 
PBS. The beakers containing PBS were then placed on an orbital shaker set at 20 
rpm.  
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Table 4.2: Treatments and controls used for testing protein/p-188 release from alginate 
coatings 
Silicon wafer# Coating Neuroprotective drug 
Wafer #1 - - 
Wafer #2 - Lysozyme 
Wafer #3 PLO coat (1%) - 
Wafer #4 PLO coat (0.1%) Lysozyme 
Wafer #5 PLO coat (0.5%) Lysozyme 
Wafer #6 PLO coat (1%) Lysozyme 
Wafer #7 PLO coat (0.1%) Chymotrypsinogen 
Wafer #8 PLO coat (0.5%) Chymotrypsinogen 
Wafer #9 PLO coat (1%) Chymotrypsinogen 
Wafer #10 - FITC-p-188 
Wafer #11 PLO coat (0.1%) FITC-p-188 
Wafer #12 PLO coat (0.5%) FITC-p-188 
Wafer #13 PLO coat (1%) FITC-p-188 
 
 
At each time point the entire 5 ml of 1xPBS was removed and replaced 
with fresh solution. The samples from each time point were then separated into 
two groups by placing them in two separate microcentrifuge tubes as shown in 
Figure 4.4. The first group of samples underwent centrifugation at 3000 rpm for 1 
min to separate the protein solution from particulate matter. In comparison, to 
the second group of samples, 100 µl of 4mg/ml EDTA was added and mixed. 
Following mixing the second group of samples also underwent centrifugation at 
3000 rpm for 1 min. The concentration of total dissolved protein in each group 
was then determined to obtain the final release profile.  
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Figure 4.4: Schematic of release study showing sample isolation and protein 
quantification 
 
4.2.6 Protein Quantification 
All samples obtained from release studies were immediately assayed for 
protein concentrations or were stored in 4°C refrigerators up to a maximum of 4 
days. Protein quantification was performed using the FluoroProfile™ Protein 
Quantification Kit (Sigma cat no. FP0010). The assay was carried out in a 96 well 
plate format using Corning black 96 well plates with flat bottoms (Coring no: 
3915). A standard curve was prepared for each protein using known 
concentrations of protein dissolved in 1xPBS or sample buffer. Using the 
standard curve unknown concentrations of proteins were calculated by 
interpolation. 
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  For the protein assay either 50 µl or 100 µl of sample were used. 
Depending on the volume of sample, an equal volume of protein assay buffer (50 
µl or 100 µl) was added to each well of the 96 well plate. Care was taken to not 
create any bubbles in the process. Once the samples and assay buffer were added 
to the respective wells, the plates were then placed on an orbital shaker (20 rpm) 
in the dark for up to 1 hour. Fluorescence quantification from the plates was 
measured using a TECAN microplate reader at an excitation wavelength of ~510 
nm and emission wavelength of ~620 nm.  
4.2.5 Poloxamer quantification: 
Quantification of poloxamer was possible due to the FITC conjugated to it 
and was performed almost immediately after the release study.  Similar to the 
protein quantification mentioned above, standard curves were constructed using 
known quantities of p-188. Using the standard curve, unknown concentrations of 
p-188 at the different time points were calculated by interpolation. Quantification 
of the FITC-p-188 was done using a TECAN reader at an excitation wavelength 
of ~485 nm and emission wavelength of ~525 nm. 
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5 RESULTS AND DISCUSSION 
The main goal of this project was to promote long term in-vivo functionality of 
silicon electrodes by delivering BDNF from alginate electrode coatings. The overall 
project consisted of two main phases. During the first phase of the project, experiments 
were performed using the spinner coating apparatus. Results from these experiments 
were used to identify the right combination of material and methodological parameters 
needed to manufacture electrode coatings of the required thickness. 
During the second phase of the project, release studies were performed from 
alginate coatings manufactured using the parameters obtained from the first phase. The 
release of two model proteins (lysozyme and chymotrypsinogen) and FITC labeled 
poloxamer (FITC-p-188) was performed in phosphate buffered saline (PBS) at 37°C. 
Results from the release studies showed the release profiles of the two model proteins 
and poloxamer over a period of 48 hours. Finally the effect of Poly-L-ornithine (PLO) 
coatings to provide controlled release was evaluated. 
5.1 Manufacturing alginate thin films 
5.1.1 Determining optimal sterilization technique 
In the past sterile alginate has been prepared either by autoclaving or by 
filtering. However, depending on the sterilization method used the physical 
properties of the alginate have been shown to vary. Therefore choosing the right 
method of sterilization for this specific application will be important.  
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Results from the sterilization experiments showed that autoclaved 4% 
alginate solutions had a much lower viscosity compared to the filtered 4% 
alginate solutions. These observations are in accord with studies which report 
autoclaving alginate (Leo W. J., 1990). Autoclaving alginate has been shown to 
cause a decrease in the degree of polymerization of the alginate molecules (Leo 
W. J., 1990). Leo et al., studied the effect of sterilization on the physical properties 
of alginate. The results of the study showed that 1% and 3% solutions of alginate 
when autoclaved at 121°C for 20 minutes measured a 78% and 86% decrease in 
viscosity respectively (Leo W. J., 1990).  
The viscosity of the alginate solution is an important variable that needs 
to be considered for producing alginate coatings via spinner coating. Highly 
viscous solutions of alginate are expected to produce thicker coatings while 
solutions of low viscosity are expected to produce relatively thinner coatings. 
The results from the spinner coating experiments showed that 4% autoclaved 
alginate solutions spin coated at 1000 rpm for 30 seconds (CaCl2
Based on the thickness measurements either 4% autoclaved alginate or 
4% filtered alginate could be used to produce electrode coatings. However to 
 crosslinked) 
produced coatings in the range of nanometers. However spin coating of 4% 
filtered alginate solution using the same parameters produced coatings in the 
lower microns (~5-6 µm). Also the coatings formed using the autoclaved alginate 
were brittle and developed cracks easily compared to the coatings manufactured 
using the filtered alginate solutions.  
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reach a final coating thickness of 20-30 µm fewer layers of filtered 4% alginate 
solution would be required. Therefore filtering alginate was chosen as the 
preferred method of sterilization.  
5.1.2 Effect of alginate concentration, velocity of rotation and spin coat duration 
Optimization of processing variables (spin-coating velocity, acceleration 
and duration) and variables associated with the polymer solution (concentration, 
molecular weight, pH, temperature etc.) is essential for consistent alginate 
coating production. Among the variables associated with the polymer solution 
all were kept constant except for the concentration of the solution. To check the 
effect of alginate concentration, solutions of two different concentrations, 2% 
(Table 5.1) and 4% (Table 5.2) were used for manufacturing electrode coatings. 
While both concentrations of alginate produced electrode coatings, a wide 
variation in thickness was observed. As seen from Table 5.1 the coatings 
manufactured using the 2% alginate solutions were much more colorful 
compared to the coatings manufactured using 4% alginate solutions (Table 5.2). 
The variation in color between the two different coatings can be attributed to the 
variation in the thicknesses of the films. Thickness variation in the films results in 
variation in the film’s surface properties by the creation of phase changes in the 
angle of refraction. The equation relating phase changes with the film’s 
thicknesses is: Φλ = nd where Φ is the phase change, λ is the wavelength, n is the 
index of refraction of the film, and d is the thickness of the film.  
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Therefore based on the reflective properties of alginate coatings, colorful 
surfaces would imply thinner coatings while colorless surfaces implied 
comparatively thicker coatings. Therefore films manufactured using the 2% 
alginate solution were a lot thinner compared to the films manufactured using 
the 4% alginate solution.  
The above observations confirmed initial expectations, since 4% alginate 
solution being highly viscous, was expected to produce comparatively thicker 
coatings. The results from the profilometer studies further confirmed the above 
observations by showing that coatings manufactured using 4% alginate solution 
(1000 rpm, 30 secs, CaCl2 crosslinked) were thicker by 2-3µm compared to 
coatings manufactured using 2% alginate solutions (1000 rpm, 30 secs, CaCl2 
crosslinked).  
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Table 5.1: Thickness and reflectance properties of alginate coatings spin coated using 2% 
filtered alginate solution and crosslinked with CaCl
 
2 
Among the different processing variables spin coating velocity and 
duration of spinning were changed keeping all else constant. Both the variables 
had a similar effect on the thickness of the alginate coatings. When the spin 
coating velocity was increased it resulted in the production of more colorful and 
hence thinner coatings. This property although not very obvious with the 
coatings manufactured using 4% alginate solutions (Table 5.2), is evident with 
the coatings manufactured using the 2% alginate solutions (Table 5.1). As seen 
from Table 5.1 a clear variation in thickness is noticed via the reflective 
properties of the coatings when the speed is increased from 1000 rpm to 3000 
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rpm. The coatings spun at 3000 rpm are colorful and a lot thinner compared to 
coatings spun at 1000 rpm.  
Table 5.2: Thickness and reflectance properties of alginate coatings spin coated using 4% 
filtered alginate solution and crosslinked with CaCl2 
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 Increasing the duration of spinning produced a very similar effect. With 
increasing duration a decrease in thickness of the coatings was observed. 
Comparison of alginate coatings (4% alginate solution, 3000 rpm) spun for 30 and 
60 seconds shows a much colorful and hence thinner coating produced by the 
latter compared to the former (Table 5.2). Thickness measurements obtained 
from the profilometer confirmed the above observations. The results from the 
profilometer showed that the thickest coating was manufactured using the 4% 
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alginate solution spun at 1000 rpm for 30 seconds (~6 µm). When the duration of 
rotation was increased to 60 seconds the thickness decreased to ~5 µm. Similarly 
when the spin coating velocity was increased to 2000 rpm or 3000 rpm the 
thickness of the coatings manufactured decreased to the range of nanometers.  
 Since coatings in the range of microns are required the parameters that 
produced the thickest film (4% alginate solution, 1000 rpm, 30 seconds) was used 
subsequently for manufacturing alginate  coatings. The parameters were chosen 
in the interest of requiring fewer layers of alginate to reach the final coating 
thickness.  
5.1.3 Slow CaCO3 crosslinking versus fast CaCl2 crosslinking 
Degradation of non-crosslinked plain alginate coatings in 1xPBS was 
found to be in the order of seconds (results not shown). Therefore to prolong the 
degradation time of the alginate coatings in 1xPBS crosslinking using divalent 
cations was necessary.  
In the past crosslinking of alginate has been done using a number of 
different methods. For this specific project two different methods of crosslinking 
alginate were evaluated (i) the slow gelling CaCO3 + GDL method and (ii) the 
fast crosslinking method using CaCl2.  
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Table 5.3: Alginate coatings manufactured using 2% alginate crosslinked using slow 
gelling CaCO3 –GDL method 
 
Table 5.1- Table 5.2 and Table 5.3-Table 5.4 show the results obtained 
after crosslinking alginate using the fast crosslinking and the slow crosslinking 
methods respectively. Comparison of the coatings manufactured using these two 
methods shows very little difference. As seen from the tables, both methods 
produced alginate coatings with colorful surfaces at high velocities (>1000rpm). 
Similarly coatings with colorful surfaces are observed when the duration of 
spinning was increased from 30 to 60 seconds. The only major difference noticed 
between the two crosslinking methods was with regards to the surface profile of 
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the alginate films. The surface profile of coatings manufactured using the slow 
gelling method was relatively uneven. This was due to the presence of insoluble 
CaCO3 crystals found on the surface. Efforts to achieve complete solubility failed 
due to the fact that the rate of Ca2+
Table 5.3
 liberation due to hydrolyzing GDL was much 
slower than the rate of drying of the film. Results from the crosslinking 
experiments showed that complete solubility and subsequent crosslinking took 
up to 8 hours following addition of fresh GDL. During this time the alginate 
films most often dried leaving un-dissolved CaCO3 crystals on the surface of the 
wafers.   shows the unevenness of the crosslinking seen in the form of 
dots on the surface of the alginate films. In comparison using an aerosolized 
spray of CaCl2 produced even crosslinking. The aerosolized spray of calcium 
chloride solution delivered the Ca2+ ions to the films without disturbing the 
surface structure. This can be seen by the even coloration on the surface of the 
thin films as seen in Table 5.1 and Table 5.2.  
Cathell et al., showed that aerosolized spray of CaCl2 is the optimal 
method for crosslinking alginate thin films (Cathell and Schauer, 2007). The 
authors of the study did not evaluate the slow-gelling method. However they 
conducted a number of studies to decipher the optimal method of crosslinking 
using CaCl2. Experiments were conducted where (i) CaCl2 was added to the 
alginate solution right before spin coating or (ii) CaCl2 was added using an 
automated dispensing mechanism to the thin films during the spin coating 
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process or (iii) thin films were immersed into solutions of CaCl2 right after spin 
coating or (iv) CaCl2 was added in the form of an aerosolized spray (Cathell and 
Schauer, 2007). Results from these studies showed that the first three 
experiments failed to produce even crosslinked alginate films. The first two 
experiments failed as they led to formation of rapidly crosslinked insoluble gels 
before alginate thin films could be manufactured. The third experiment failed 
since it often led to the disruption of the alginate films when immersed in a 
solution of CaCl2. The aerosolized spray of CaCl2 was found to be the optimal 
method for crosslinking films produced via spinner coating.  
Table 5.4: Alginate coatings manufactured using 4% alginate crosslinked using slow 
gelling CaCO3 –GDL method 
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5.1.4 Characterization of multilayered alginate thin films 
Based on observation, coatings measuring approximately 6 µm of 
thickness were produced by spin coating 4% filtered alginate at 1000rpm for 30 
seconds (Figure 5.1). Release studies performed in saline using the alginate 
coatings showed that the films degraded completely within a matter of minutes. 
Therefore to increase degradation times, thicker films manufactured using 
multiple coats (layers) of alginate was required.  
To prepare thicker films 1, 2, 3 and 4 coatings of alginate was performed 
on a single silicon wafer using the method shown in Figure 4.2. Thickness 
measurements obtained using the profilometer showed that films ranging from 
5-80 µm in thickness could be manufactured by increasing the number of 
alginate layers. The average thickness recorded for the 1, 2, 3 and 4 alginate 
coatings was 6.14 µm, 26.16 µm, 46.53 µm and 80.25 µm respectively (Figure 5.1). 
Although promising, increasing thickness using multiple coatings also increased 
surface unevenness. Looking at Figure 5.1 we see that the errors associated with 
film thicknesses increased with increase in the number of coatings. The film 
manufactured using 4 coatings recorded the maximum standard error of 9.12 µm 
while the film manufactured using a single coating recorded the least error of 
0.37 µm.  
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Figure 5.1: Change in thickness with number of alginate coatings (Alginate 4%, 0.45 µm 
filtered, 10% CaCl2 crosslinked) 
 
 When compared to the single coated films, films manufactured using 4 
coatings took several hours to degrade in 1xPBS at 37°C. However they weren’t 
used since they exceeded the initial design requirement for a coating that 
measured less than 50 µm. In comparison films manufactured using 2 or 3 
alginate coatings fit the initial design requirement, they recorded very little error 
in their thickness profiles, 2.02 µm and 2.64 µm respectively. Experiments on 
protein loading showed that films manufactured using 2 and 3 coatings could be 
loaded with physiologically relevant quantities of protein. 
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Based on the results either 2 or 3 layered alginate coatings could have 
been used for subsequent protein release studies. However the 3 layered alginate 
film was chosen over the 2 layered film since they were expected to degrade over 
a longer period, hence sustaining protein release for a longer period of time. 
5.1.5 Protein-alginate interactions 
The results from the protein solubility tests showed that proteins with 
high isoelectric points (pI > 7) formed precipitates when mixed with 4% filtered 
alginate. On the other hand low pI proteins (pI < 7) like BSA completely 
dissolved in the alginate solutions (Table 5.5). Although all three high pI proteins 
(Lysozyme- pI – 11.35, α-Chymotrypsin- pI – 9.1 and Chymotrypsinogen A- pI – 
9.1 ) formed precipitates at a final concentration of 4mg/ml, very strong protein-
alginate interactions were observed only in lysozyme. The protein-alginate 
interaction seemed comparatively weaker in chymotrypsin and 
chymotrypsinogen. When the final protein concentration was reduced to 2mg/ml 
both chymotrypsin and chymotrypsinogen dissolved in alginate with vigorous 
mixing. However lysozyme (pI – 11.35) continued to form a thick white 
precipitate even at a lower concentration of 2mg/ml.    
The above observations are concurrent with the results of Wells et al. 
(Wells and Sheardown, 2007). Wells et al., tried to encapsulate high pI proteins 
(Lysozyme and Chymotrypsin) and low pI proteins (BSA) in 3% alginate 
solutions to form microspheres. The results of the study showed 1 ml of 30 
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mg/ml solutions of both lysozyme and chymotrypsin interacted with 3% alginate 
solution forming a precipitate (Wells and Sheardown, 2007). On the other hand 
BSA completely dissolved in the alginate solution up to a concentration of 
15mg/ml (Wells and Sheardown, 2007). While Wells et al., report precipitation 
with high pI proteins, Vögelin et al. reports successful solubility of BDNF (pI 
9.1). The study reports successful mixing of 600 µg of BDNF with 1 ml of 3% 
sodium alginate solution without any signs of precipitation (Vögelin et al., 2006). 
Table 5.5: Solubility of high and low pI proteins in 4% filtered alginate solution 
Protein 
Isoelectric 
point (pI) 
Size of 
protein 
(kDa) 
Solubility 
Bovine Serum Albumin (BSA) 4.7 66 soluble 
Lysozyme 11.35 14.7 precipitate formed 
Chymotrypsin 9.1 25 precipitate formed 
Chymotrypsinogen 9.1 25.6 precipitate formed 
Brain Derived Neurotrophic Factor (BDNF) 9.1 27.2 N/A 
 
Taking into consideration the results from the solubility test and from 
other studies, it is clear that a high pI protein like BDNF will become 
electropositive at pH up to their pI and hence react with the negative carboxyl 
groups of the alginate forming a precipitate at high concentrations. It could be 
possible to overcome this problem by using a lower concentration of BDNF. 
However the lower concentration will create problems in achieving loading of 
physiologically relevant quantities of BDNF to promote neuron survival. 
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5.2 Protein release studies 
5.2.1 Optimal method for loading proteins into alginate films 
Results from the solubility test clearly showed that loading of proteins by 
mixing with alginate solutions is not feasible. Therefore two different methods 
for loading proteins were tested. Proteins were loaded either by (i) immersing 
the dry alginate coatings into a protein solution, or (ii) by rehydrating the films 
using a pipette containing 100-175 µl of concentrated protein solution. 
Comparison of the two methods showed that the latter led to more 
efficient protein loadings compared to the former. Dry alginate coatings when 
immersed into a protein solution rehydrated, expanded rapidly and therefore 
detached from the underlying silicon wafers making them unusable for 
subsequent protein release studies. In comparison the group of films that were 
rehydrated with 100-175 µl remained intact even after protein loading. Loading 
proteins by rehydrating using a pipette also ensured no wastage of protein 
during the loading process.   
5.2.2 Protein Release Profiles – Lysozyme 
The fluoroprofile protein kit was used to create standard curves using 
known quantities of lysozyme and chymotrypsinogen. Both the standard curves 
showed that protein concentrations ranging from 48.8 ng/ml to 200 µg/ml 
occurred over a linear profile (Appendix A). Also the R2 values for both the 
curves were 0.99 showing the goodness of fit. Using interpolation within the 
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linear range, the unknown concentrations of proteins at the different time points 
were calculated. The calculated concentrations were then used to build the 
release profile for the different proteins. Figure 5.2 shows the release profile of 
lysozyme obtained using the above method.   
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Figure 5.2: Lysozyme release from alginate thin films in 1xPBS, 37°C and 40 rpm 
 
As seen from the release curve (Figure 5.2) the protein lysozyme starts 
exponential release immediately after it is placed in the PBS solution. Complete 
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release of the protein occurs within the first three hours, well short of the 
anticipated 3-4 day release. This three hour release is consistent with results 
obtained from other studies. Wells et al., showed that complete release of 
lysozyme in PBS occurred within three hours from alginate microbeads (Wells 
and Sheardown, 2007).  
Looking past the three-hour time point the lysozyme release curve 
becomes flat indicating no more protein release. In comparison the control curve 
(No-Lysozyme) gradually increases starting at the 3 hour time point and reaches 
saturation at the 5-6 hour time point. This increase seen in the control curve is 
small and does not indicate the presence of any protein. Instead it is expected to 
be indicative of the degradation of the alginate in the release medium.  
5.2.3 Effect of PLO Coating on Controlled Protein Release 
Initial studies on protein release showed that complete release of proteins 
took place over a three hour period, well short of the anticipated period of 3-4 
days. Therefore to prolong protein release, alginate thin films were coated with 
PLO. Previously, studies have shown that PLO can prolong protein release by (i) 
altering the network pore size of crosslinked alginate gels (Tobias et al., 2001)  
and/or (ii) increasing degradation time by forming polycation complexes with 
the alginate (Gombotz and Wee, 1998).  
Figure 5.3 and Figure 5.4 show lysozyme release profiles obtained from 
alginate films coated with PLO. While the former shows the release profile over a 
56 
 
period of 48 hours the latter shows the release profile for the first 5 hours of 
protein release.  
As seen in Figure 5.3, PLO-coated and uncoated films loaded with 
lysozyme have different release profiles compared to the negative controls (No- 
PLO No- Lysozyme and PLO (1%) No- Lysozyme). The negative controls do not 
contain any protein and therefore show zero release.  
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Figure 5.3: Lysozyme release from PLO coated alginate thin films over 48 hours 
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Comparison of PLO- coated and uncoated alginate films shows very little 
difference in their respective release profiles. As seen from Figure 5.3 protein 
release from alginate films coated with PLO (1%) and PLO (0.1%) resemble 
protein release from the uncoated alginate film (No-PLO Lysozyme). Therefore 
PLO coatings on alginate films had very little effect on prolonging protein 
release.  
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Figure 5.4: Lysozyme release from PLO coated alginate thin films – first five hours 
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Looking closely at the first 5 hours of lysozyme release (Figure 5.4) we see 
that both the uncoated (No-PLO Lysozyme) and coated films (PLO (1%) 
Lysozyme and PLO (0.1%) Lysozyme) show very similar release profiles. At time 
zero all the films show zero release save the film coated with 0.1% of PLO (PLO 
(0.1%) Lysozyme). The film coated with 0.1% PLO, releases approximately 25% 
of protein at time zero. This sudden release seen here is expected to be due to the 
detachment of the alginate film from the surface of the silicon wafer, resulting in 
protein diffusion from both sides of the film.  
Release profiles of lysozyme and chymotrypsinogen from alginate films 
coated with different concentrations of PLO showed very little difference. It was 
expected that increasing the PLO concentration would result in smaller alginate 
network pores and/or thicker coatings on the surface of the alginate films due to 
more complex formation. Therefore films with 1% PLO coating were expected to 
have a much slower release compared to films coated with 0.5% PLO or 0.1% 
PLO. However the results showed that coatings of different PLO concentrations 
have very little effect on the release profiles of the different proteins.  
This could be due to the fact that (i) the pore size in the rate controlling 
PLO membrane was too large, allowing free diffusion of protein or (ii) the PLO 
coating did not completely coat the surface of the alginate films leaving areas of 
the alginate uncovered and therefore allowing free diffusion of protein. While 
both possibilities are equally likely, the latter seems to have been the likely 
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problem in this particular project. Observations made during the release studies 
showed that the alginate films detached from the surface of the silicon wafers 
within the first hour after placing in 1xPBS. The observations are therefore 
indicative of an incomplete PLO coat that did not go all the way around the 
alginate film.  
As mentioned earlier the protein lysozyme has an isoelectric point of 11. 
Therefore at a pH of 6.4 (pH of 0.45 µm filtered 4% alginate solution) it is 
expected to interact strongly with any negative groups that remain after 
crosslinking alginate. In comparison chymotrypsinogen has a lower isoelectric 
point of 9.1, similar to BDNF, and is expected to experience weaker interactions 
with alginate. Therefore the two different proteins are expected to have different 
release profiles due to their different isoelectric points. However the results from 
the study showed that proteins, lysozyme and chymotrypsinogen have very 
similar release profiles.  
During the release studies a quantity of alginate particulate matter was 
noted in the release medium. To check if the particulate matter had any protein 
entrapped in it, samples obtained at different time points were either (i) 
centrifuged or (ii) treated with EDTA. Centrifugation was used to separate the 
dissolved protein from any particulate matter that might have been present in 
the release medium. Figures 5.2-5.4 show the amounts of dissolved protein found 
in the release medium at each time point. As seen from the figures almost all 
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samples (except controls) show 100% release, meaning all of the loaded protein 
was released from the alginate films and subsequently dissolved in the release 
medium. 
 In the past, studies have used EDTA to dissolve alginate gels, 
subsequently releasing any protein or cell encapsulated in it  (Grandolfo et al., 
1993). If the total release of the protein increases following EDTA addition it 
would provide evidence for the presence of protein in the alginate particulate 
matter.  
Figure 5.5 shows the release curves obtained from the EDTA treated 
samples and the centrifuged samples. As seen from the figure both 
centrifugation and EDTA treatment produces similar trends in the release 
profile. Little difference is noticed in the lysozyme release profile between the 
centrifuged and the EDTA treated samples. This confirms the fact that the 
majority of the protein lysozyme in the release medium is found in the dissolved 
form. Very little protein, if any remained in the alginate particulate matter. This 
is not surprising since any protein released in the alginate particles would diffuse 
out very rapidly, unless it was electrostatically bound to the alginate.  
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Figure 5.5: Lysozyme and Chymotrypsinogen release from 1% PLO coated alginate films 
– EDTA treated samples versus centrifuged samples 
 
5.2.4 Poloxamer release profile 
The alginate film’s ability to encapsulate and release poloxamer-188 (p-
188) was evaluated. To track the release of poloxamer FITC labeled p-188 was 
loaded and released from the alginate coatings.  
Figure 5.6 shows the release of poloxamer (p-188) from alginate films 
over a period of 12 hours. As seen from the figure all films show burst profiles 
with complete release of p-188 within the first 3 hours. The uncoated film (No-
PLO Poloxamer) shows 20% release at time zero, reaching a maximum of 55% at 
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the 3 hour time point. Similarly all the coated films (PLO (0.1%) Poloxamer, PLO 
(0.5%) Poloxamer, PLO (1%) Poloxamer) show ~30% release at time zero, 
reaching a maximum of 70% at the 3 hour time point. Neither the coated nor the 
uncoated films report 100% release of poloxamer. This could be because of (i) an 
error in the loading of p-188 or (ii) photobleaching of the FITC attached to the 
poloxamer. While the first choice is unlikely, photobleaching of FITC seems to be 
the probable cause. 
Alginate debris was again formed during the release study as mentioned 
earlier. To check if any poloxamer remained in the alginate particulate matter, 
samples from different time points were either (i) centrifuged or (ii) EDTA 
treated. Poloxamer release from the two groups however looked similar, 
implying that all of the released p-188 was found dissolved in the release 
medium. Very little p-188, if any remained in the alginate particulate matter. 
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Figure 5.6: Effect of PLO coatings (0.1%, 0.5% and 1% PLO) on the release profile of p-
188 in alginate 
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6 CONCLUSIONS 
In conclusion, this present study clearly showed the feasibility of manufacturing 
alginate coatings for silicon electrodes by a spin coating technique. The silicon can be 
coated with multiple layers and these final coating can be of a multi valent cationic 
polymer. The thickness of the coatings can be varied by altering material parameters 
(concentration, viscosity) and/or spin coating parameters (velocity of rotation and speed 
of rotation). Results from the study clearly showed that coatings ranging anywhere from 
5 µm - 80µm could be produced by placing layers of alginate on top of one another.   
Results from the protein-solubility test showed that alginate-protein interactions 
exist for high pI proteins like BDNF (pI 9.1). However, loading of proteins into the 
alginate coatings can be accomplished by rehydrating the dried alginate coatings using 
small volumes (100-200µl) of concentrated protein solution.  
The results from the in-vitro release studies showed that physiologically relevant 
quantities of neurotrophins can be loaded and released from the alginate coatings. Also, 
the alginate coatings manufactured using spinner coating techniques are versatile. Apart 
from delivering proteins, the coatings can also be used to delivery other neuroprotective 
substances like poloxamer-188. 
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7 RECOMMENDATIONS 
• One of the major problems that was encountered during the release studies was the 
dissociation of the alginate films from the surface of the silicon wafers during protein 
release. The PLO coated alginate films were found to dissociate from the silicon 
wafer substrates within the first 30 minutes of release. Therefore protein diffusion 
continued unabated even in the presence of PLO coatings. An electropositive coating 
on the surface of the silicon wafer could be applied to prevent this problem. Either 
polyethyleneimine coatings of PLO coatings on the silicon wafers could be used.  
• Only three different concentrations of PLO were tested in this project. A more 
concentrated solution of PLO, >1% (w/v) could be tested to see if more concentrated 
PLO can prolong protein release.  
• The in-vitro release studies showed that complete release of proteins occurred within 
the first three hours. It is possible that in-vivo release profiles in the brain may be 
longer from the in-vitro release profiles performed in 1xPBS at 37°C. Therefore 
electrodes coated with alginate, loaded with either protein or p-188 should be tested 
in a tissue phantom (e.g. agarose) and then in-vivo.  
• The brain extra cellular matrix consists mainly of proteoglycans. Hyaluronic acid 
(HA) which is a natural component of the brain could be used as an alternate to 
alginate. HA hydrogels can be investigated for their ability to provide controlled 
release of neurotrophins. 
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APPENDIX A: CALCULATIONS FOR PROTEIN LOADING 
 
Study details 
References 
 
(Giehl M. 
K., 1996b) 
(Gillespie N. 
L., 2003) 
(Tuszynsk
i et al., 
1996) 
(Hammond, 
1999) 
(Vavrek et 
al., 2006) 
Neuron Type 
corticospi
nal 
neurons 
auditory 
neurons 
hypogloss
al nerve 
corticospina
l neurons 
corticospi
nal 
neurons 
Volume of Injury 
Induced (mm^3) 
52 N/A N/A 52 N/A 
When did delivery 
start? 
Immediate
ly after 
injury 
5 days after 
ototoxin 
exposure 
Immediate
ly after 
injury 
Immediatel
y after 
injury 
Immediate
ly after 
injury 
Amount of BDNF 
delivered (µg/hr) 
0.5 0.016 0.05 0.5 0.5 
Time of delivery 
(days) 
7 28 14 14 14 
End Result 
promotes 
survival 
promotes 
survival 
promotes 
survival 
promotes 
long term 
survival 
promotes 
connectio
ns 
Amount of BDNF 
to be delivered 
(µg/hr) 
0.005 N/A N/A 0.005 N/A 
Total amount of 
BDNF to be 
delivered (µg) 
0.346 N/A N/A 0.346 N/A 
 
A literature search for all papers that showed survival of neurons post injury 
using BDNF delivery was performed. A few prospective papers were identified and 
were used for further review. Information such as the volume of injury induced, 
amount of BDNF delivered, length of delivery and end result were tabulated.  
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Using the information obtained from previous studies the total amount of BDNF 
that would have to be delivered to rescue neurons injured by the silicon electrode 
was calculated.  
Calculations: 
Volume of injury induced by silicon electrode implantation = 0.5 mm * 0.5 mm * 
2mm = 0.5 mm^3 
Amount of BDNF to be delivered (µg/hr) = (Amount of BDNF delivered from study 
(µg/hr) * Volume of Injury expected due to silicon electrode (mm3)/ Volume of Injury 
induced from study (mm3) 
Total amount of BDNF to be delivered (µg) = Amount of BDNF to be delivered 
(µg/hr) * 24 hours * 3 days 
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APPENDIX B:  STANDARD CURVES FOR RELEASE STUDIES 
 
The following standard curves were made using known concentrations of lysozyme and 
chymotrypsinogen.  
  
Figure A-1: Standard curve for Lysozyme extending over a range: 48.8 ng/ml - 200 µg/ml 
 
Figure A-2: Standard curve for chymotrypsinogen extending over a range: 48.8 ng/ml - 
200 µg/ml 
 
 
 
R2 = 0.99 
y = 0.16x +
−
 0.0040 
R2 = 0.99 
y = 0.21x +
−
 0.0084 
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APPENDIX C: PROTOCOL TO MAKE FILTERED 4% ALGINATE 
1. Weight out the required amount of alginate using a weighing scale. To prepare 
500 ml of 1% alginate solution weight out 5g of pharmaceutical grade alginate 
power. 
2. Take 500 ml of distilled water in a beaker. Preparation of solution can be done 
using a magnetic stirrer.  
3. Since alginate takes a long time to dissolve add the alginate powder in small 
quantities over intervals of time until all the alginate is completely in solution.  
4. Take some of the prepared 1% alginate solution in a 5 or 10 ml syringe. Fit the 
syringe with a 0.45 µm Nalgene filter. Slowly filter the alginate without applying 
too much pressure. If sterile alginate is required for experimentation then this 
should be done into a sterile container and all subsequent steps should be 
performed in the laminar flow hood using sterile technique.  
5. Place the filtered 1% alginate solution in 50 ml tubes and freeze them using 
liquid nitrogen in a beaker.  
6. Once the solution is completely frozen, place the 50 ml tubes in a -80 deg C 
freezer. Let the tubes sit in the freezer for 3-4 hours.  
7. Take the tubes out of the freezer and place them in the freeze drying apparatus. 
Freeze drying the alginate solution may take anywhere from 3-4 days.  
8. Take the free-dried alginate and weight them using a weighing scale. This will 
help determine if there is any moisture left in the alginate. 
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9. The 0.45 µm filtered alginate can then be used to prepare a 4% alginate solution. 
To prepare 50 ml of 4% alginate solution take 2g of 0.45 µm free-dried alginate 
and dissolve it in 50 ml of distilled water.  
10. Use a mechanical stirrer with the blades to prepare the 4% alginate solution. As 
mentioned earlier add the alginate in small quantities to ensure complete mixing.   
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APPENDIX D: PROTOL FOR CLEANING SILICON WAFERS 
1. Break the wafers carefully. Use a diamond cutter or just use of the end of the 
spatula. 
2. Break a single silicon wafer from the manufacturer into a number of smaller 2 cm 
x 2cm wafers. The dimensions of the wafers need not be exact. Normalization of 
all data can be done at a later time to account for the different sized wafers.    
3. Place the wafers inside a 1000-1500 ml beaker. Fill it up with 250 ml of distilled 
water.  
4. To the distilled water add 50 ml of Ammonium Hydroxide and 50 ml of 
Hydrogen Peroxide (30%). The ratio of water, ammonium hydroxide and 
hydrogen peroxide should be 5:1:1.  
5. Make sure that all the wafers in the beaker are completely submerged in the 
alkali solution. Add a little distilled water if required to keep the wafers 
submerged completely.  
6. Let the beaker sit on a hot plate until it boils.  
7. Let the solution boil for 5 mins. Make sure that the temperature of the solution 
does not go above 72 degrees C. 
8. Wash the beaker/wafers at least 4 times with distilled water. Make sure that there 
is no ammonium hydroxide left in the beaker or the wafers.  
9. Now repeat the same process with water, concentrated Hydrochloric acid (conc. 
HCL), hydrogen peroxide (30%) in the ratio 5:1:1.  
10. Allow the solution to boil for 5 mins.  
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11. Rise with distilled water at least 4 times to completely remove any HCL or 
peroxide that may be present in the wafers.  
12. Let the wafers air dry overnight.  
13. Wipe the wafer clean using wipes.  
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APPENDIX E: SPINNER COATING ALGINATE ON SILICON 
WAFERS 
1. Solutions of 2% and 4% alginate filtered using 0.45 µm Nalgene filters were 
prepared as mentioned earlier.  
Note: You will need to have pre-cleaned wafers available before starting this 
procedure. The silicon wafers are cleaned using the RCA cleaning procedure 
mentioned above.  
2. Take a 1 ml syringe and fill it up with the 2% or 4% alginate solution.  
3. Open the lid of the spinner coater and place a clean silicon wafer on the disk. 
Make sure that the silicon wafer is centered. This will be important to ensure that 
an even coating is formed on the surface of the silicon wafer.  
4. Open the air supply connected to the vaccum pump. Once the flow of air has 
been established turn on the vaccum pump attached to the spinner coating 
apparatus. The vaccum pump will help hold the silicon wafer in place during the 
coating procedure. 
5. Slowly cover the surface of the silicon wafer using the alginate solution. Care 
should be taken to avoid any bubbles from forming during this procedure. If 
bubbles are formed use a plastic Pasteur pipet to remove them from the surface. 
6. After application wait for 1-2 minutes for the alginate solution to spread evenly 
on the surface of the silicon wafer.  
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7. In the meantime input the required parameters such as (i) speed of rotation (ii) 
acceleration and (iii) time of spinning into the spinner coating apparatus. 
8. Run the spinner coater by hitting the “RUN” button. 
9. Wait for the spinner coater to stop completely before opening the lid.  
10. Turn off the vaccum pump. Use forceps to gently remove the silicon wafer from 
the spinning stage.  
11. Let the alginate film air dry by placing it outside. Other methods include blow 
drying the surface using forced air or placing the alginate on a hot plate.  
12. Slow drying of the alginate is better since fast drying could produce cracks on the 
surface of the film.  
13. However when multiple layers of alginate need to be spin coated (for example 3 
or 4 layers), the 3rd or 4th
14. After completion of multiple/single layer(s) of alginate crosslinking of the 
alginate is done using a 10% CaCl2 solution (10 g of CaCl2 dissolved in 100 ml of 
distilled water). 
 coat may take a very long time to dry. At these times a 
hot plate could be used to speed the drying process. However it is important to 
ensure that the heat is kept low. Cracks will form when if the temperature is too 
high or if the wafer is kept on the hot plate for a very long time. At any time 
some amount of moisture should remain in the film to keep it intact. Complete 
drying of the film will produce cracks making it un-usable for release studies.  
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15. The 10% CaCl2 solution is sprayed on the surface of the films using a spray bottle. 
Use 4-5 sprays using a 3 oz spray bottle or enough to cover the entire surface of 
the alginate thin film using CaCl2 solution.  
